Document is current
Any future updates will be listed below
-
Authors
Saleem, Javeria https://orcid.org/0000-0003-4295-7057
Zakar, Rubeena
Butt, Muhammad Salman
Kaleem, Rameeza
Chaudhary, Asif
Chandna, Jaya
Jolliffe, David A.
Piper, Joseph
Abbas, Zaigham
Tang, Jonathan C. Y. https://orcid.org/0000-0001-6305-6333
Fraser, William D.
Freemantle, Nick
Prendergast, Andrew J. https://orcid.org/0000-0001-7904-7992
Martineau, Adrian R. https://orcid.org/0000-0001-5387-1721
-
Funding
Funding for this research was provided by:
Thrasher Research Fund (15080)
- License Information
-
More Information
Article History
Received: 20 July 2024
Accepted: 5 March 2025
First Online: 15 March 2025
Competing interests
: ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd; support for attending meetings from Pharma Nord Ltd and Abiogen Pharma Ltd; receipt of consultancy fees from DSM Nutritional Products Ltd and Qiagen Ltd; receipt of a speaker fee from the Linus Pauling Institute; participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195); and unpaid work as a Programme Committee member for the Vitamin D Workshop. All other authors declare that they have no competing interests.
